Abstract： To investigate the potential risk factors for parotid gland failure after intensity-modulated radiotherapy (IMRT) for nasopharyngeal carcinoma (NPC). Methods The clinical data of 1096 NPC patients who underwent IMRT in our hospital from January 2005 to December 2012 were analyzed retrospectively. Among these patients, 13 patients experienced parotid gland recurrence, and the recurrence in 12 patients was analyzed. A case-control study was performed with the side of the parotid gland with recurrence as the case group and the side of the parotid gland without recurrence as the control group. The association of parotid gland failure with the extent of tumor invasion, IMRT dose distribution, and local recurrence was analyzed. The differences between groups were analyzed with χ2 test or Fisher′s the exact probability test. Results Among the 12 patients, 11 had stage III-IV primary NPC;after definitive IMRT, 9 had local tumor residues. The median time of parotid gland recurrence was 16(8-43) months. Of all the patients who experienced recurrence, 8 had recurrence in the superficial lobe of the parotid gland, 1 in the deep lobe, and 3 in both superficial and deep lobes. Recurrence was in the same side of primary tumor (P<0.001). Compared with the controls, the side of the parotid gland with recurrence had higher rate of cervical puncture/surgery (P=0.025). Parotid gland recurrence was often complicated by ipsilateral lymph node recurrence (67% vs. 8%, P=0.003), as well as the tendency of ipsilateral primary lesion recurrence (42% vs. 8%;P=0.059). Conclusions For NPC patients, the recurrence rate in the parotid gland is very low. Parotid gland recurrence may be related to locally advanced NPC, residues after treatment, the history of cervical puncture/surgery, and locoregional recurrence. The low radiotherapy dose in the parotid gland caused by IMRT may be an important reason for parotid gland recurrence.
. Failure in region of parotid gland after definitive intensity-modulated radiotherapy for Nasopharyngeal Carcinoma[J]. Chinese Journal of Radiation Oncology, 2016, 25(3): 212-215.
[1] Jemal A,Bray F,Center MM,et al. Global cancer statistics[J].CA Cancer J Clin,2011,61(2):69-90.DOI:10.3322/caac.20107. [2] Kam MK,Chau RM,Suen J,et al. Intensity-modulated radiotherapy in nasopharyngeal carcinoma:dosimetric advantage over conventional plans and feasibility of dose escalation[J].Int J Radiat Oncol Biol Phys,2003,56(1):145-157.DOI:10.1016/S0360-3016(03)00075-0. [3] Chia-Hsien Cheng J,Clifford-Chao KS,Low D.Comparison of intensity modulated radiation therapy (IMRT) treatment techniques for nasopharyngeal carcinoma[J].Int J Cancer,2001,96(2):126-131.DOI:10.1002/ijc.1004. [4] Peng G,Wang T,Yang KY,et al. A prospective,randomized study comparing outcomes and toxicities of intensity-modulated radiotherapy vs.conventional two-dimensional radiotherapy for the treatment of nasopharyngeal carcinoma[J].Radiother Oncol,2012,104(3):286-293.DOI:10.1016/j.radonc.2012.08.013. [5] Lai SZ,Li WF,Chen L,et al. How does intensity-modulated radiotherapy versus conventional two-dimensional radiotherapy influence the treatment results in nasopharyngeal carcinoma patients?[J].Int J Radiat Oncol Biol Phys,2011,80(3):661-668.DOI:10.1016/j.ijrobp.2010.03.024. [6] Pow EH,Kwong DL,McMillan AS,et al. Xerostomia and quality of life after intensity-modulated radiotherapy vs.conventional radiotherapy for early-stage nasopharyngeal carcinoma:initial report on a randomized controlled clinical trial[J].Int J Radiat Oncol Biol Phys,2006,66(4):981-991.DOI:10.1016/j.ijrobp.2006.06.013. [7] Hsiung CY,Ting HM,Huang HY,et al. Parotid-sparing intensity-modulated radiotherapy (IMRT) for nasopharyngeal carcinoma:preserved parotid function after IMRT on quantitative salivary scintigraphy,and comparison with historical data after conventional radiotherapy[J].Int J Radiat Oncol Biol Phys,2006,66(2):454-461.DOI:10.1016/j.ijrobp.2006.04.033. [8] Clifford-Chao KS,Ozyigit G,Tran BN,et al. Patterns of failure in patients receiving definitive and postoperative IMRT for head-and-neck cancer[J].Int J Radiat Oncol Biol Phys,2003,55(2):312-321.DOI:10.1016/S0360-3016(02)03940-8. [9] 罗京伟,徐国镇,高黎,等.鼻咽癌IMRT后的少见治疗失败方式——腮腺转移[J].中华放射肿瘤学杂志,2007,16(2):154.DOI:10.3760/j.issn:1004-4221.2007.02.018. Luo JW,Xu GZH,Gao L,et al. The treatment failure model of nasopharyngeal carcinoma with intensity modulated radiation therapy:parotid gland metastasis[J].Chin J Radit Oncol,2007,16(2):154.DOI:10.3760/j.issn:1004-4221.2007.02.018. [10] 中国鼻咽癌临床分期工作委员会.2010鼻咽癌IMRT靶区及剂量设计指引专家共识[J].中华放射肿瘤学杂志,2011,20(4):267-269.DOI:10.3760/cma.j.issn.1004-4221.2011.04.001. China working committee on clinical staging of nasopharyngeal carcinoma.2010 expert consensus of nasopharyngeal carcinoma intensity modulated radiation therapy dose and target design guidelines[J].Chin J Radiat Oncol,2011,20(4):267-269.DOI:10.3760/cma.j.issn.1004-4221.2011.04.001. [11] Cao CN,Luo JW,Gao L,et al. Clinical characteristics and patterns of failure in the parotid region after intensity-modulated radiotherapy for nasopharyngeal carcinoma[J].Oral Oncol,2013,49(6):611-614.DOI:10.1016/j.oraloncology.2013.02.001. [12] Pan WR,Suami H,Corlett RJ,et al. Lymphatic drainage of the nasal fossae and nasopharynx:preliminary anatomical and radiological study with clinical implications[J].Head Neck,2009,31(1):52-57.DOI:10.1002/hed.20926. [13] Mckean ME,Lee K,McGregor IA.The distribution of lymph nodes in and around the parotid gland:an anatomical study[J].Br J Plast Surg,1985,38(1):1-5.DOI:10.1016/0007-1226(85)90078-5. [14] Chong VF, Fan YF.Parotid gland involvement in nasopharyngeal carcinoma[J].J Comput Assist Tomogr,1999,23(4):524-528. [15] Cannon DM,Lee NY.Recurrence in region of spared parotid gland after definitive intensity-modulated radiotherapy for head and neck cancer[J].Int J Radiat Oncol Biol Phys,2008,70(3):660-665.DOI:10.1016/j.ijrobp.2007.09.018.
2016, Vol. 25 
